Literature DB >> 26592968

Postencephalitic epilepsy and drug-resistant epilepsy after infectious and antibody-associated encephalitis in childhood: Clinical and etiologic risk factors.

Sekhar C Pillai1,2, Shekeeb S Mohammad1, Yael Hacohen3, Esther Tantsis1,2, Kristina Prelog4, Elizabeth H Barnes5,6, Deepak Gill2, Ming J Lim3,7, Fabienne Brilot1, Angela Vincent3, Russell C Dale1,2.   

Abstract

To define the risk factors for postencephalitic epilepsy (PE) and drug-resistant epilepsy (DRE) in childhood following infectious and autoimmune encephalitis, we included 147 acute encephalitis patients with a median follow-up of 7.3 years (range 2-15.8 years). PE was defined as the use of antiepileptic drugs (AEDs) for ≥24 months, and DRE was defined as the persistence of seizures despite ≥2 appropriate AEDs at final follow-up. PE and DRE were diagnosed in 31 (21%) and 15 (10%) of patients, respectively. The features during acute encephalitis predictive of DRE (presented as odds ratio [OR] with confidence intervals [CIs]) were status epilepticus (OR 10.8, CI 3.4-34.3), visual disturbance (6.4, 1.4-29.9), focal seizures (6.2, 1.9-20.6), magnetic resonance imaging (MRI) hippocampal/amygdala involvement (5.0, 1.7-15.4), intensive care admission (4.7, 1.4-15.4), use of >3 AEDs (4.5, 1.2-16.1), MRI gadolinium enhancement (4.1, 1.2-14.2), any seizure (3.9, 1.1-14.4), and electroencephalography (EEG) epileptiform discharges (3.9, 1.3-12.0). On multivariable regression analysis, only status epilepticus remained predictive of DRE in all models. DRE was common in herpes simplex virus (3/9, 33%) and unknown (8/40, 20%) encephalitis, but absent in acute disseminated encephalomyelitis (ADEM) (0/32, 0%), enterovirus (0/18), and anti-N-methyl-d-aspartate receptor-NMDAR encephalitis (0/9). We have identified risk factors for DRE and demonstrated "high-risk," and "low-risk" etiologies. Wiley Periodicals, Inc.
© 2015 International League Against Epilepsy.

Entities:  

Keywords:  Autoimmune; Encephalitis; Epilepsy; Infection; Outcome

Mesh:

Substances:

Year:  2015        PMID: 26592968     DOI: 10.1111/epi.13253

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

1.  Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies.

Authors:  Mar Carreño; Christian G Bien; Ali A Asadi-Pooya; Michael Sperling; Petr Marusic; Martin Elisak; Jose Pimentel; Tim Wehner; Rajiv Mohanraj; Juan Uranga; Asier Gómez-Ibáñez; Vicente Villanueva; Francisco Gil; Antonio Donaire; Nuria Bargalló; Jordi Rumià; Pedro Roldán; Xavier Setoain; Luis Pintor; Teresa Boget; Eva Bailles; Mercè Falip; Javier Aparicio; Josep Dalmau; Francesc Graus
Journal:  Epilepsy Res       Date:  2016-12-15       Impact factor: 3.045

2.  Perisylvian vulnerability to postencephalitic epilepsy.

Authors:  Claude Steriade; Lara Jehi; Balu Krishnan; Marcia Morita-Sherman; Ahsan N V Moosa; Stephen Hantus; Patrick Chauvel
Journal:  Clin Neurophysiol       Date:  2020-05-11       Impact factor: 3.708

3.  Increased rates of sequelae post-encephalitis in individuals attending primary care practices in the United Kingdom: a population-based retrospective cohort study.

Authors:  Julia Granerod; Nicholas W S Davies; Parashar P Ramanuj; Ava Easton; David W G Brown; Sara L Thomas
Journal:  J Neurol       Date:  2016-10-20       Impact factor: 4.849

Review 4.  Molecular Mechanisms in the Genesis of Seizures and Epilepsy Associated With Viral Infection.

Authors:  Wolfgang Löscher; Charles L Howe
Journal:  Front Mol Neurosci       Date:  2022-05-09       Impact factor: 6.261

5.  Postencephalitic epilepsy in dogs with meningoencephalitis of unknown origin: Clinical features, risk factors, and long-term outcome.

Authors:  Adriana Kaczmarska; Roberto José-López; Michał Czopowicz; Kali Lazzerini; Guillaume Leblond; Catherine Stalin; Rodrigo Gutierrez-Quintana
Journal:  J Vet Intern Med       Date:  2020-01-28       Impact factor: 3.333

6.  Efficacy and potential predictors of vagus nerve stimulation therapy in refractory postencephalitic epilepsy.

Authors:  Siqi Liu; Zhonghua Xiong; Jing Wang; Chongyang Tang; Jiahui Deng; Jing Zhang; Mengyi Guo; Yuguang Guan; Jian Zhou; Feng Zhai; Guoming Luan; Tianfu Li
Journal:  Ther Adv Chronic Dis       Date:  2022-01-13       Impact factor: 5.091

7.  Vagus Nerve Stimulation Therapy for the Treatment of Seizures in Refractory Postencephalitic Epilepsy: A Retrospective Study.

Authors:  Yulin Sun; Jian Chen; Tie Fang; Lin Wan; Xiuyu Shi; Jing Wang; Zhichao Li; Jiaxin Wang; Zhiqiang Cui; Xin Xu; Zhipei Ling; Liping Zou; Guang Yang
Journal:  Front Neurosci       Date:  2021-08-19       Impact factor: 4.677

8.  GluR3B Antibody Was a Biomarker for Drug-Resistant Epilepsy in Patients With Focal to Bilateral Tonic-Clonic Seizures.

Authors:  Qingwei Lai; Qingyun Li; Xinyu Li; Heng Wang; Wei Zhang; Xiaotao Song; Peng Hu; Ruiqin Yao; Hongbin Fan; Xingshun Xu
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

Review 9.  Neurocritical care for Anti-NMDA receptor encephalitis.

Authors:  Kuang-Lin Lin; Jann-Jim Lin
Journal:  Biomed J       Date:  2020-04-21       Impact factor: 4.910

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.